Dengue: A Complete Research Overview (2026)

Published 2026-06-18 · Mosticare Editorial

Dengue is a viral infection transmitted by Aedes aegypti and Aedes albopictus mosquitoes that puts an estimated 5.6 billion people, more than half the world's population, at risk, causes 100-400 million infections each year, and is the fastest-expanding mosquito-borne viral disease on Earth. There is no specific antiviral treatment; clinical management is supportive, and prevention rests on vector control, household protection, and (where approved) vaccination. This article is the canonical Mosticare reference for the disease in 2026, written for clinicians, public-health professionals, science journalists, and informed consumers across the European Union.

Why this overview, and why now

The week of 15 June 2026 was a textbook case of why dengue demands a research-grade, not news-grade, treatment. The same 48-hour window carried (1) the World Health Organization's 2026 World Dengue Day communications and its refreshed global-burden framing, (2) the World Mosquito Program's fourth Annual Review, 16.1 million people protected across 15 countries, 1.5 million dengue cases prevented, US$455 million saved in healthcare costs, and (3) the opening of the Asia Dengue Summit 2026 in Singapore. Surrounding news in the same window also carried the first credible 2026 reports of a newly introduced dengue strain in Sri Lanka and 210+ imported arbovirus cases in metropolitan France. The pattern is clear: dengue is a disease whose centre of gravity is shifting year by year, and any single news cycle captures only one slice of a much larger epidemiological arc.

This article is a static, evergreen reference that grounds the reader in the disease itself, the virus, the vectors, the serotypes, the clinical spectrum, the vaccines, the prevention innovations, and the climate-driven expansion, and provides the citable primary sources that the news cycle relies on. For Mosticare specifically, it sits as the pillar article for the dengue topic cluster, with our Europe-anchored and Brazil-anchored blog posts as supporting spokes. The companion canonical wiki entry is knowledge/wiki/diseases/dengue.md, kept current with the most recent EU and global datapoints.

1. The virus

Dengue virus (DENV) is a single-stranded, positive-sense RNA virus of the genus Flavivirus (family Flaviviridae). Its ~10.7 kilobase genome encodes a single polyprotein that is cleaved co- and post-translationally into three structural proteins (capsid, premembrane / membrane, envelope) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The virion is approximately 50 nm in diameter, enveloped, and icosahedral; the envelope protein carries the receptor-binding and membrane-fusion functions that mediate host-cell entry and is the principal target of neutralising antibodies.

There are four antigenically distinct serotypes, DENV-1, DENV-2, DENV-3, and DENV-4, defined by neutralisation assays. Genetic sequencing further resolves each serotype into multiple genotypes, which themselves drift measurably over decades. The four serotypes share roughly 65-70% amino-acid identity at the envelope protein; the cross-reactive but not cross-neutralising antibody response to non-homologous serotypes is the immunological foundation of the disease's most dangerous clinical feature, antibody-dependent enhancement, discussed in §4. All four serotypes cause the full clinical spectrum of disease, and infection with one serotype provides lifelong homotypic immunity but only short-lived (months to ~2 years) heterotypic cross-protection.

The virus is maintained in nature in two transmission cycles: a sylvatic cycle in non-human primates and forest-dwelling Aedes mosquitoes (Southeast Asia and West Africa, with sporadic spillover to humans), and an urban cycle in Aedes aegypti and Aedes albopictus and human hosts. The urban cycle is the source of essentially all human public-health burden.

2. Transmission

Dengue is transmitted to humans almost exclusively through the bite of an infective female Aedes mosquito. The principal vectors are Aedes aegypti (the primary global vector) and Aedes albopictus (the Asian tiger mosquito, which is the principal vector in Europe and the temperate-margins of the dengue map). Other Aedes species, Ae. polynesiensis, Ae. scutellaris, Ae. niveus, sustain local transmission in restricted Pacific and South-East Asian foci but are not significant at the global scale.

The transmission cycle within a competent mosquito is governed by the extrinsic incubation period (EIP), the time between the mosquito taking an infected blood meal and the mosquito being able to transmit the virus through its saliva. The EIP is temperature-dependent: at 25 °C it is roughly 8-12 days; at 30 °C it shortens to ~5-7 days; below ~18 °C viral replication effectively halts. The temperature sensitivity of the EIP is one of the principal mechanisms by which climate change is driving the geographic expansion of dengue: warmer summers mean more days above the EIP threshold within a single transmission season, and warmer winters mean the EIP can complete in a wider latitudinal range.

A mosquito remains infective for life. Female Aedes mosquitoes typically take a blood meal every 2-4 days during their gonotrophic cycle and may take multiple partial meals between oviposition events, a behaviour that increases both their vectorial capacity and the risk of interrupting the cycle with household protection (screens, closed doors and windows). Vertical (transovarial) transmission has been documented and may allow the virus to persist through adverse seasons in the egg stage, although the epidemiological significance of this pathway in driving seasonal resurgence remains debated.

Human-to-mosquito transmission efficiency is itself variable. The viraemia curve in a human dengue case peaks around the time of defervescence and declines sharply over the following 5-7 days; mosquitoes feeding on a viraemic host during this window pick up enough virus to initiate an infection. People with subclinical or pre-symptomatic infection, by definition not yet isolating themselves, can therefore seed local transmission cycles, which is one reason why community-level vector control is a non-substitutable complement to individual case isolation.

3. Global burden

Dengue is the most geographically widespread arthropod-borne virus on Earth, and its burden has grown approximately eightfold over the past two decades. The WHO 2024 dengue fact sheet and the Bhatt et al. 2013 Nature burden paper frame the canonical numbers; the WHO World Dengue Day 2026 campaign updates and re-states them in the most quotable single-frame form available today.

The 2024 calendar year was, on the WHO retrospective, the highest-burden dengue year ever recorded. The Americas were the global epicentre: Brazil alone reported over 6.6 million probable dengue cases in 2024 (Ministry of Health) and 1.7 million in 2025, before the integrated 2026 programme, Butantan single-dose vaccine, Fiocruz/World Mosquito Program Wolbachia releases at biofactory scale, ovitrap surveillance across 1,600 municipalities, cut the first-quarter 2026 case count by 75% (227,500 vs 916,400 in 2025). The 2026 Americas season is now the cleanest natural-experiment evidence base available for the integration of vaccine, biocontrol and surveillance; see the Mosticare Brazil coverage for the operational write-up.

South-East Asia and the Western Pacific carry the second and third largest regional burdens respectively, with hyperendemic co-circulation of all four serotypes in many urban areas, the immunological substrate for the antibody-dependent enhancement dynamics discussed in §4. Africa is widely understood to be substantially under-reported; seroprevalence surveys routinely detect community exposure in countries with no formal surveillance programme, and the WHO has flagged African surveillance as a priority gap.

4. The four serotypes and antibody-dependent enhancement

The four serotypes are individually capable of causing the full clinical spectrum of disease, but they are not immunologically interchangeable. A first infection with one serotype (a "primary" infection) typically produces a self-limited febrile illness or asymptomatic seroconversion and confers lifelong immunity to that serotype plus a few months to ~2 years of cross-protection against the others. As that cross-protection wanes, the immune response to a subsequent infection with a different serotype (a "secondary" or "heterotypic" infection) can paradoxically increase the risk of severe disease. The mechanism is antibody-dependent enhancement (ADE): sub-neutralising cross-reactive antibodies bind to the virion and facilitate its entry into Fcγ-receptor-bearing cells (monocytes, macrophages, some dendritic-cell subsets), increasing viral replication per cell and amplifying the host innate-immune response. The resulting cytokine cascade and the complement-activation profile are the proximal drivers of the plasma leakage, haemorrhagic manifestations, and organ impairment that define severe dengue.

The epidemiological consequence is that the introduction of a new serotype into a population already exposed to one or more of the others is a major risk amplifier. This is the immunological backdrop to the 2026 Sri Lanka "newly introduced strain" datapoint: a population without prior exposure to the circulating variant faces a population-wide primary-infection wave, with severe-dengue risk concentrated in those previously exposed to other serotypes. It is also why vaccine design is so difficult: a vaccine must be tetravalent (protective against all four serotypes) without producing the sub-neutralising, ADE-prone antibody profile in any of them.

5. Clinical spectrum

Dengue's clinical spectrum is famously wide. The WHO 2009 classification, which replaced the older dengue fever / dengue haemorrhagic fever / dengue shock syndrome schema, divides the disease into dengue without warning signs, dengue with warning signs, and severe dengue. The categories are clinically actionable because the case-fatality rate with appropriate supportive care is below 1%, while untreated severe dengue can reach 20%.

Roughly 75% of dengue infections are asymptomatic or sufficiently mild that the patient does not present to care. Symptomatic cases typically follow an incubation period of 4-10 days (median 5-7), then a febrile phase of 2-7 days characterised by:

• Abrupt-onset high fever (often 39-40 °C)
• Severe headache
• Retro-orbital pain
• Myalgia and arthralgia (the historical name "breakbone fever" derives from this)
• Nausea, vomiting, and a maculopapular or erythematous rash
• Leukopenia, thrombocytopenia, and rising haematocrit on laboratory workup

The febrile phase often defersvesces around day 3-7, and the critical phase begins in the 24-48 hours around defervescence. The critical phase is the window of plasma leakage, haemorrhagic manifestations, and organ impairment that defines severe dengue. Warning signs that mark the transition from "dengue with warning signs" to "severe dengue" include:

1. Severe abdominal pain
2. Persistent vomiting (≥3 episodes in 24 hours, or vomiting with clinical dehydration)
3. Clinical fluid accumulation (pleural effusion, ascites)
4. Mucosal bleeding (gums, nose, vaginal)
5. Lethargy or restlessness
6. Liver enlargement (>2 cm)
7. Rapidly rising haematocrit with falling platelet count

Severe dengue itself is defined by (a) severe plasma leakage leading to shock or respiratory distress, (b) severe bleeding, or (c) severe organ involvement (hepatic, neurological, cardiac, renal). Mortality in severe dengue without appropriate care is reported in the 2-5% range and can reach 20% in untreated shock; with appropriate fluid resuscitation and intensive monitoring, it is below 1%.

Two clinical features are worth highlighting. First, severe dengue is not confined to secondary infection: primary infection in infants with maternal antibody (a special case of passive ADE) and primary infection in adults with particular risk factors (diabetes, obesity, pregnancy, age ≥65) can also progress. Second, the "critical" window is narrow and easy to miss, a patient who looks well at defervescence can deteriorate within hours, which is why the WHO and most national guidelines recommend inpatient monitoring through the critical phase for any patient with warning signs, even if the initial presentation looks reassuring.

6. Diagnosis

Diagnosis rests on three pillars: epidemiological context (travel or residence in a transmission area, exposure to confirmed cases, calendar week within Aedes activity season), clinical presentation (the febrile syndrome above), and laboratory confirmation. The choice of laboratory test depends on the day of illness relative to symptom onset.

• NS1 antigen detection (ELISA or rapid immunochromatographic test). Detects the non-structural protein 1 secreted by infected cells during the acute viraemic phase. Useful from day 1 to day 5; sensitivity highest in primary infection. A negative NS1 in a strongly suspect secondary infection is not informative.
• RT-PCR (or other nucleic-acid amplification tests). Gold standard for serotype identification and viral load quantification. Useful in the first 5-7 days of illness; declining sensitivity from day 5 onwards as viraemia resolves.
• IgM / IgG serology (ELISA or rapid test). IgM rises from around day 5-7 and remains detectable for 2-3 months; IgG rises from day 7-10 and persists for years (lifelong in secondary infection). A fourfold rise in IgG on paired acute/convalescent samples is the most useful single serological confirmation, but it is retrospective.

A particular diagnostic difficulty is the serological cross-reactivity with other flaviviruses, Zika, yellow fever, West Nile, Japanese encephalitis, which complicates IgM interpretation in patients with prior flavivirus exposure or yellow-fever vaccination. Most public-health laboratories now run paired dengue / Zika / chikungunya panels in the appropriate epidemiological context, and pan-flavivirus RT-PCR followed by sequencing is the standard for outbreak confirmation. Newer point-of-care tests combine NS1 with IgM/IgG to give a more useful first-pass result; their performance in real-world field conditions is improving but still meaningfully below laboratory ELISA.

7. Treatment

There is no specific antiviral therapy for dengue. Management is supportive and is, in the severe-disease context, time-critical. The cornerstone of care is judicious fluid management, sufficient to maintain end-organ perfusion through the plasma-leakage window, but not so aggressive as to precipitate fluid overload once leakage resolves. WHO and US CDC protocols divide management into groups based on the presence of warning signs and the phase of illness; the essential principles are:

• Dengue without warning signs: outpatient management with oral rehydration, paracetamol (NOT NSAIDs or aspirin, which worsen the bleeding risk), and daily review through the critical window.
• Dengue with warning signs: inpatient monitoring, isotonic crystalloid fluid resuscitation titrated to clinical response, daily or twice-daily haematocrit and platelet counts.
• Severe dengue: intensive care, isotonic fluid boluses followed by titrated infusion, blood-product transfusion where indicated (rare, and only with active bleeding or critical thrombocytopenia with bleeding), management of organ-specific complications (hepatic, neurological, renal).

Adjunct therapies (corticosteroids, intravenous immunoglobulin, recombinant activated factor VII, pentoxifylline, antivirals such as lovastatin or celgosivir) have been investigated in small trials but none has shown consistent benefit, and the standard of care remains supportive. The most important clinical fact is a non-pharmacological one: the case-fatality rate in severe dengue drops from 20% to below 1% with appropriate supportive care, and the marginal investment in early recognition, monitoring, and fluid management is the single highest-yield clinical action available.

8. Prevention

Dengue prevention is layered and is not the responsibility of any single actor. The WHO-endorsed framework is integrated vector management (IVM): the combination of (a) source reduction (eliminating or treating breeding sites), (b) larval control (larviciding, biological control, environmental management), (c) adult mosquito control (targeted indoor residual spraying, ultra-low-volume fogging during outbreaks), (d) personal protection (repellents, clothing, household barriers), and (e) community engagement. No single intervention is sufficient at scale; the Brazilian 2026 75% drop is the cleanest evidence to date that the IVM combination works at population scale when it is actually integrated.

Personal protection in 2026 rests on three pillars:

1. Topical repellents (DEET, picaridin / icaridin, IR3535, oil of lemon eucalyptus / PMD, and, more recently, naturally-derived compounds such as patchouli oil) applied to exposed skin according to label instructions. Effective for 4-8 hours depending on formulation and conditions; require re-application and behavioural compliance.
2. Protective clothing, light-coloured, long-sleeved shirts and long trousers, especially during peak biting hours. Aedes albopictus in particular is a daytime biter, which is one reason why clothing and household barriers are more useful for dengue than for purely nocturnal mosquito-borne diseases.
3. Household barriers, window and door screens, intact door seals, bed nets, and air-conditioning where available. These are the most reliable intervention for residents of affected areas: they protect continuously during peak biting hours without requiring active behavioural compliance, and they are the WHO and ECDC recommended component of IVM for households in transmission areas.

Community and municipal action is the second tier: larviciding of container habitats, environmental management to reduce standing water, public-awareness campaigns, and surveillance using ovitraps and BG-Sentinel traps to track vector density and trigger interventions. Most affected EU countries now run vector-surveillance programmes through their national public-health agencies; public participation (reporting tiger-mosquito sightings, allowing property access for inspection) materially improves the effectiveness of these programmes.

Vaccination (see §9) is the third tier in populations where licensed vaccines are available, but vaccine coverage does not displace any of the above, it complements them. A vaccine that protects an individual from symptomatic disease does not prevent that individual from being bitten and contributing to onward transmission if they are subsequently exposed; vector control remains the only currently available tool to suppress transmission at the population level.

9. Vaccines

The dengue vaccine landscape in 2026 is dominated by two licensed products, Sanofi Pasteur's Dengvaxia (CYD-TDV) and Takeda's Qdenga (TAK-003), and by the rising South-led candidate Butantan-DV, the single-dose dengue vaccine developed by Instituto Butantan in São Paulo and rolled out at scale in Brazil in 2025-2026.

Dengvaxia (CYD-TDV) is a live-attenuated tetravalent chimeric yellow-fever / dengue vaccine first licensed in 2015. Its pivotal trials showed a strong protective effect in seropositive recipients but an increased risk of hospitalisation for severe dengue in seronegative recipients who later experienced their first natural infection, the ADE signal predicted from the underlying immunology. As a result, Dengvaxia is licensed only for individuals with documented prior dengue infection, which makes it operationally complex in low-transmission settings where the serostatus of the population is unknown. It is not the leading EU-relevant product.

Qdenga (TAK-003) is a live-attenuated tetravalent dengue vaccine based on a DENV-2 backbone. The pivotal TIDES trial (Biswal et al. 2019, NEJM) demonstrated 80.2% overall efficacy against symptomatic dengue at 18 months, with efficacy maintained across serotypes and, critically, without the serostatus restriction that limited Dengvaxia. The European Medicines Agency authorised Qdenga in December 2022 for individuals aged 4 and older regardless of prior dengue serostatus, making it the first dengue vaccine broadly deployable in EU travel-medicine and outbreak-response contexts. Real-world effectiveness data accumulated through 2024 and 2025 has been broadly consistent with the pivotal-trial profile; the product is now the reference dengue vaccine for European clinicians and for most endemic-country national immunisation programmes.

Butantan-DV is the live-attenuated tetravalent single-dose dengue vaccine developed at Instituto Butantan and rolled out in Brazilian pilot cities in 2025 and 2026. The single-dose regimen is a critical operational advantage for low- and middle-income countries where completing a two-dose schedule is logistically difficult; the Brazil Ministry of Health's April 2026 announcement and the Agência Brasil reporting place the Butantan vaccine as one of the three load-bearing interventions in Brazil's 75% YTD 2026 case-count drop. Phase 3 readouts in 2024 and 2025 reported efficacy in the 70-80% range, broadly comparable to TAK-003 on the available data, with an ADE signal that has not been reported to date in post-market surveillance. Butantan-DV is currently a Brazil-led product; export to other endemic countries and a future EMA submission are expected to follow the 2026 pilot data.

Beyond these, the development pipeline in 2026 includes: mRNA-based dengue vaccine candidates (following the platform validation from COVID-19), pan-serotype monoclonal-antibody prophylaxis for outbreak containment, virus-like-particle vaccines, and a number of recombinant subunit candidates. The pan-serotype antiviral development path is also active: the ideal profile is an oral, short-course, broadly active antiviral that could be used both therapeutically and as outbreak containment. None of these has yet reached the regulatory-authorisation threshold.

10. Vector biology

Aedes aegypti is the primary global dengue vector. It is a small, dark mosquito with characteristic white lyre-shaped markings on the thorax and white-banded legs. It is highly anthropophilic (preferring human blood meals), strongly synanthropic (living in and around human dwellings), and a daytime biter with peak activity in the early morning and late afternoon. Container-breeding: Ae. aegypti females lay their eggs in small, clean-water artificial containers, discarded tyres, plant saucers, roof gutters, water-storage jars, cemetery vases, which makes urban environments its native habitat. The species is temperature-sensitive (development essentially halts below ~16 °C) and is therefore limited, in the absence of heating, to tropical and subtropical latitudes; in Europe its established range is essentially restricted to Madeira (Portugal) and limited Black-Sea coastal areas.

Aedes albopictus (the Asian tiger mosquito) is the secondary global dengue vector and the primary European vector. It is slightly larger than Ae. aegypti, with a distinctive single white stripe down the centre of the thorax and bold white-banded legs that give the "tiger" name. Originally a South-East Asian forest-edge species, it has expanded its global range dramatically over the past 50 years, in part through the international trade in used tyres (which carry desiccation-resistant eggs). It is also a daytime biter, also container-breeding, but it is significantly more cold-tolerant than Ae. aegypti, its eggs can survive European winters in diapause, allowing the species to establish itself across temperate climates. As of mid-2025, Ae. albopictus is established in 16 EU/EEA countries and 369 regions, up from 114 regions a decade ago (ECDC distribution maps). The species is responsible for essentially all autochthonous European dengue, chikungunya, and Zika transmission events to date.

A critical vector-biology fact is that Aedes control is categorically different from malaria-vector control. Anopheles mosquitoes (malaria) tend to bite at night, rest on indoor walls after feeding, and breed in larger bodies of standing water, interventions target indoor residual spraying, long-lasting insecticidal nets, and larval source management in rice paddies. Aedes mosquitoes bite by day, rest in hidden outdoor locations where indoor residual spraying is ineffective, and breed in small artificial containers that are dispersed across every household, interventions must therefore focus on household barriers, personal repellents, and peridomestic source reduction, with community-wide container-habitat elimination campaigns as the population-level complement.

11. Climate and geographic expansion

Dengue's geographic range is expanding in a pattern that is now unambiguously attributable to a combination of climate change, urbanisation, international travel, and the failure of legacy vector-control programmes. The ECDC's standing characterisation, Europe enters a new normal of mosquito-borne disease, is supported by the surveillance data: locally acquired dengue cases on the European mainland rose from 71 in 2022 to more than 300 in 2024, with France, Spain, and Italy at the frontline. The 2026 season is the first in which the ECDC's autochthonous-arbovirus surveillance updates are being tracked in real time by a coordinated EU-wide medical community; the first in-season ECDC update is typically published in late June, after the Mosticare publication of this article.

The mechanism is a combination of:

• Warming-driven EIP completion. Warmer summers mean more days within the temperature range where the extrinsic incubation period can complete within a single transmission season. In temperate Europe, the EIP threshold was historically crossed in only the warmest summers; climate change has moved it to the median summer.
• Vector range expansion. Aedes albopictus has expanded from 114 EU/EEA regions a decade ago to 369 as of mid-2025, and modelling studies project further northward expansion under all reasonable climate scenarios. Northern-European capitals, Paris, Vienna, Zagreb, Frankfurt, London, were formally declared climatically suitable for Ae. albopictus establishment in a January 2026 European Commission environment report.
• Imported case seeding. EU/EEA countries report approximately 2,000-5,000 imported dengue cases annually, with numbers tracking the global epidemiological situation. The 2024 global surge was reflected in markedly increased European imports, creating more "seed" cases that could potentially trigger local transmission. The 2026 numbers, 164 imported dengue, 43 chikungunya, 4 Zika in France from 1 May to 14 June alone (Santé publique France, 17 June 2026), are consistent with another high-import year.
• Failure of legacy programmes. The large-scale Aedes control programmes that protected southern Europe through the mid-20th century, larviciding, source reduction, public-health infrastructure, have been substantially dismantled in most EU countries since the 1970s, in line with the perception that autochthonous mosquito-borne disease was a thing of the past. The ECDC and national agencies are now rebuilding this infrastructure from a much lower base.

For the European consumer specifically, the consequence is that dengue is no longer a "tropical" disease. It is a Mediterranean-summer disease, with the transmission season running approximately June to November and peak risk in August and September. Household-level protection, window and door screens, intact seals, air-conditioning where available, is now a recurring annual preparedness task for households across southern and central Europe, not a one-off response to a discrete outbreak. The Mosticare editorial position on this is that household screening is infrastructure, not luxury, in the modern European dengue landscape.

12. Innovation in prevention

The 2010s and 2020s have produced a remarkable expansion in the vector-control toolkit, with three technologies now at or near population-scale deployment.

Wolbachia-based biocontrol uses the Wolbachia endosymbiont (a naturally occurring intracellular bacterium) to reduce the ability of Aedes aegypti to transmit dengue, Zika, chikungunya, and yellow fever. The mechanism is either (a) population suppression, releasing male mosquitoes carrying a Wolbachia strain that causes embryonic lethality when males mate with wild-type females, or (b) population replacement, releasing male and female mosquitoes carrying a Wolbachia strain that blocks viral replication, so the released mosquitoes and their offspring gradually replace the wild population with a virus-resistant one. The World Mosquito Program's Wolbachia method is the leading example of the population-replacement approach and is the technology behind the 16.1M-people-protected / 1.5M-cases-prevented / US$455M-saved cumulative figures. Cluster-randomised trials in Yogyakarta (Indonesia) showed a 77% drop in dengue incidence in release zones; the Singapore Project Wolbachia trial published in the NEJM in 2026 reported more than 70% fewer dengue infections in residents of treated areas; the Brazilian Ministry of Health's 72-municipality / 70M-people Wolbachia rollout is the first national-scale deployment. The 2025 Nature feature on the Fiocruz/World Mosquito Program biofactory in Curitiba, the largest Wolbachia mosquito factory in the world, is the clearest single description of the production scale now feasible.

Sterile insect technique (SIT) uses radiation-sterilised male mosquitoes released into the wild to suppress the population through sterile-male mating. The IAEA has been a long-standing supporter of SIT for Aedes control, and the technique has been deployed at operational scale in parts of Italy, Spain, and Brazil. The 2026 EU SIT programmes remain small relative to the total Ae. albopictus population, but the cost-per-mosquito is dropping and the technology is increasingly being integrated into municipal IVM programmes.

Gene drive technologies, including CRISPR-based population suppression and replacement drives, are still in the research phase. The Target Malaria consortium and a small number of Aedes-focused programmes are pursuing regulatory pathway development, but no gene-drive product is yet authorised for environmental release. The technical and ethical issues are substantial and the regulatory timeline is measured in decades, not years.

Alongside these headline technologies, ongoing work continues on next-generation larvicides (Bti and other biological agents), autodissemination stations (devices that allow adult mosquitoes to carry larvicide back to their breeding sites), and AI-driven surveillance (image-recognition of Aedes eggs in ovitraps, AI-assisted breeding-site detection from drone imagery, real-time vector-density forecasting). The 2026-2030 horizon is the first in which the full IVM toolkit, vaccination, Wolbachia or SIT population modification, household barriers, AI-augmented surveillance, and rapid outbreak response, is plausibly available as an integrated package to a national public-health programme.

13. Outlook

Three trends will define the dengue landscape over the next 5 years.

First, the geographic expansion will continue. Climate-driven Aedes range expansion, increasing international travel, and the slow rebuilding of European public-health mosquito-control infrastructure mean that the EU autochthonous case count is highly likely to keep rising through at least 2030, with the first sustained EU transmission chains expected within the next 3-5 years in the most climatically suitable areas (coastal Mediterranean France, Spain, Italy, Greece, and the Adriatic). The role of imported-case seeding in triggering these chains is well-established; the Ae. albopictus vector is in place; the missing variable is whether the public-health response can be mobilised at sufficient speed when the first local chains appear.

Second, the vaccine landscape will diversify. Butantan-DV and the mRNA-based candidates will likely reach wider global availability in the late 2020s, and the operational question will shift from "is there a vaccine" to "how do we integrate vaccine into IVM." A vaccine that protects an individual from severe disease does not interrupt transmission; only integrated vector management does. The countries that learn the IVM integration lesson earliest, Brazil being the most cited current example, will see the largest population-level benefit.

Third, the IVM toolkit will be increasingly digital. AI-augmented vector surveillance, real-time outbreak forecasting, and rapid Wolbachia / SIT deployment capability will progressively replace the legacy paper-and-knock-on-door surveillance model. The countries and municipalities that invest in this digital infrastructure now will be the ones that maintain a controllable dengue curve through the 2030s.

For European consumers specifically, the operational implication is the same one that has applied since 2010: household-level protection, window and door screens, intact seals, daytime-biting-safe clothing and repellents, breeding-site elimination around the home, is the foundation of any effective personal dengue strategy, and is now a recurring annual task for households across southern and central Europe. Vaccines protect travellers; screens protect homes. The two are complementary, not substitutes.

Frequently asked questions

Is dengue the same as "breakbone fever"?

Yes. "Breakbone fever" is the historical name for dengue, derived from the severe myalgia and arthralgia that characterise the acute febrile phase. The name fell out of clinical use in the 20th century but is widely used in patient-facing communications in endemic countries.

Can you catch dengue more than once?

Yes. There are four serotypes, and infection with one provides lifelong immunity only to that serotype. A second infection with a different serotype is the most common route to severe dengue, because of the antibody-dependent enhancement mechanism. Subsequent third and fourth infections are progressively less likely to cause severe disease, because the cross-protective immunity gradually broadens.

Is there a cure for dengue?

No. There is no specific antiviral therapy. Clinical management is supportive, fluid resuscitation through the critical phase is the highest-yield intervention, and the case-fatality rate in severe dengue drops from ~20% to below 1% with appropriate care. Several pan-serotype antivirals are in development but none has reached the regulatory-authorisation threshold.

Is there a dengue vaccine available in Europe?

Yes. Takeda's Qdenga (TAK-003) was authorised by the European Medicines Agency in December 2022 for individuals aged 4 and older regardless of prior dengue serostatus. It is now the reference dengue vaccine for European travel medicine and outbreak response. Sanofi's Dengvaxia is also licensed but restricted to seropositive individuals in most settings. Butantan-DV (single-dose) is the rising South-led candidate, currently available in Brazil with wider rollout expected later in the decade.

Can you catch dengue in Europe?

Yes. Locally acquired (autochthonous) dengue cases have been confirmed in France, Spain, Italy, Croatia, and Portugal (Madeira, 2012 outbreak) since 2010, with mainland-EU cases rising from 71 in 2022 to more than 300 in 2024. The trend is unambiguously upward, driven by climate-driven Aedes albopictus range expansion and the volume of imported cases from endemic regions. The Mosticare editorial position is that household-level protection (window and door screens, intact seals, daytime-biting-safe clothing) is now a recurring annual Mediterranean preparedness task, not a one-off response to a discrete outbreak.

What time of year is dengue risk highest in Europe?

The transmission season runs approximately June to November, with peak risk in August and September when mosquito populations and temperatures are both at their highest. The ECDC publishes weekly autochthonous-arbovirus updates during this period; the first in-season update is typically published in late June.

Can dengue be fatal?

Yes. Severe dengue can be fatal, but the case-fatality rate with appropriate clinical management is below 1%. Untreated severe dengue can reach 20% mortality. The highest-yield clinical action is early recognition of warning signs and timely fluid resuscitation through the critical phase. If you or a family member develops the warning signs above after a febrile illness during Aedes activity season, seek medical attention immediately.

Is it safe for a pregnant woman to travel to a dengue-endemic area?

Dengue in pregnancy carries specific risks (vertical transmission, premature birth, neonatal dengue) and the WHO recommends that pregnant women defer non-essential travel to high-transmission areas where possible. Travel-medicine consultation is essential for any pregnant traveller to a dengue-endemic area; Qdenga is not currently licensed for use in pregnancy. Household protection is the most reliable intervention for residents of endemic areas.

What is the connection between dengue and the weather?

Warmer temperatures accelerate the extrinsic incubation period of dengue virus in the mosquito, which shortens the time between mosquito infection and human infectivity. Warmer winters allow Aedes albopictus to survive in regions that were previously too cold. The combination is the principal mechanism by which climate change is driving the geographic expansion of dengue, including the emergence of autochthonous European transmission.

Why are there so many dengue vaccines and so few malaria vaccines?

The two diseases are not directly comparable, and the relative vaccine-development difficulty is the opposite of what the public often assumes. Dengue has four antigenically distinct serotypes that all need to be protected against, with an additional constraint (no ADE) on the antibody profile; the live-attenuated platforms (Dengvaxia, Qdenga, Butantan-DV) have navigated this with varying degrees of success. Malaria has a single species (Plasmodium falciparum) as the primary target but a complex multi-stage lifecycle that no single antigen protects against; the RTS,S and R21/Matrix-M vaccines that reached WHO recommendation in 2023-2024 target only the liver-stage and have lower per-dose efficacy. Both are real and continuing fields; the takeaway is that vaccine difficulty is not predictable from the number of organisms involved.

References (primary sources)

1. WHO, Dengue and severe dengue fact sheet (regularly updated).
2. WHO, World Dengue Day 2026 campaign page. 5.6 billion people at risk; 100-400 million infections per year.
3. ECDC, Dengue surveillance and disease data for the EU/EEA. Weekly autochthonous arbovirus updates during Aedes activity season.
4. ECDC, Risk assessment for dengue on mainland EU/EEA. Annual assessment.
5. US CDC, Clinical features and warning signs of dengue. Standard clinical reference.
6. EMA, Qdenga (TAK-003) EPAR. Product information and EU authorisation history.
7. NEJM, Singapore Project Wolbachia trial (2026). >70% reduction in dengue risk in release zones.
8. Nature, Fiocruz/World Mosquito Program Wolbachia biofactory, Curitiba (2025). The largest Wolbachia factory in the world.
9. World Mosquito Program, Wolbachia method global impact. 16.1M people protected across 15 countries, 1.5M dengue cases prevented, US$455M healthcare costs averted (Annual Review 2025).
10. Wilder-Smith, A. et al. (2019). Dengue. The Lancet, 393(10169), 350-363. The standard modern clinical review.
11. Bhatt, S. et al. (2013). The global distribution and burden of dengue. Nature, 496(7446), 504-507. Foundational burden-of-disease paper.
12. Biswal, S. et al. (2019). Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. NEJM, 381(21), 2009-2019. The TIDES trial of TAK-003.
13. Agência Brasil, Brazil Ministry of Health 75% YTD dengue drop in 2026. April 2026 reporting on the integrated programme.
14. Brazil Ministry of Health, official 2026 dengue announcement. Source for the 1.4M-vaccinated / 300K-health-worker figures.
15. Halstead, S. B. (2007). Dengue. The Lancet, 370(9599), 1644-1652. The classic ADE reference.
16. Guzman, M. G. et al. (2016). Dengue infection. Nature Reviews Disease Primers, 2, 16055.
17. Messina, J. P. et al. (2019). The current and future global distribution and population at risk of dengue. Nature Microbiology, 4(9), 1508-1515.
18. European Centre for Disease Prevention and Control (2024). Autochthonous transmission of dengue virus in EU/EEA, 2010-2024.
19. Sousa, C. A. et al. (2012). Ongoing outbreak of dengue type 1 in the Autonomous Region of Madeira, Portugal. Eurosurveillance, 17(49).
20. Succo, T. et al. (2016). Autochthonous dengue outbreak in Nîmes, South of France. Eurosurveillance, 21(21).
21. Rocklöv, J. & Tozan, Y. (2019). Climate change and the rising infectiousness of dengue. Emerging Topics in Life Sciences, 3(2), 133-142.
22. Laporta, G. Z. et al. (2023). Global distribution of Aedes aegypti and Aedes albopictus in a climate-change scenario of RCP 4.5. Insects, 14(1), 49.

Companion Mosticare content (internal)

• knowledge/wiki/diseases/dengue.md, Canonical internal wiki article, kept current with the most recent EU and global datapoints (2026 World Dengue Day update block, Sri Lanka new-strain datapoint, France SpF 210+ imported cases).
• Dengue in Europe 2026: from tropical postcard to local outbreak, Europe-anchored spoke.
• Brazil's dengue cases fell 75% in early 2026. Three things changed at once., Brazil / Wolbachia-anchored spoke.
• Singapore Project Wolbachia trial reports >70% reduction in dengue risk, Science spoke.
• Luciano Moreira named to TIME 100 for Wolbachia work in Brazil, Science spoke.
• WHO Malaria Day 2026 and the funding gap, Cross-disease context.
• Chikungunya transmission threshold at 13 °C, implications for European range expansion, Cross-disease vector-biology context.
• intelligence/wmp/2026-06-15-dengue-day-newsletter.md, Source filing for the WMP World Dengue Day 2026 newsletter that informed the 5.6 B / 100-400 M framing and the 16.1 M / 1.5 M / US$455 M numbers.

This article is informational and is intended for clinicians, public-health professionals, science journalists, and informed consumers. It does not constitute medical advice. If you suspect dengue infection, particularly during Aedes activity season in a transmission area, seek medical attention promptly.

About Mosticare: Mosticare develops chemical-free mosquito protection solutions, built to WHO standards for treated nets, EU BPR compliant, permethrin-only, for homes, businesses, and communities across Europe. Our mission: a green, mosquito-free life for every European. Learn more.

This article is editor-of-record by Adrian Christiansen (CEO, Mosticare Global). It is drafted by Clou D. Clover (Chief Research Officer) and polished by the Babel editorial pipeline. Corrections: corrections@mosticare.org.